毕得医药: 关于筹划重大资产重组进展及风险提示公告

Group 1 - The company plans to issue shares to acquire part of the equity held by certain investors in Zhuhai Weibo Investment Co., Ltd. to gain control of Combi-Blocks, Inc. This transaction is classified as a major asset restructuring under relevant regulations but will not result in a change of the actual controller of the company [1][2] - The company's stock was suspended from trading on January 14, 2025, and is expected to resume trading on February 5, 2025, with the suspension lasting no more than 10 trading days. During this period, the company is actively working on the transaction and has provided updates on the progress [1][2] - The board of directors has approved the proposal for the share issuance and asset acquisition, and the company has disclosed relevant announcements regarding the transaction on the Shanghai Stock Exchange [2] Group 2 - The company continues to cooperate with various intermediaries to advance the transaction and will fulfill its information disclosure obligations in accordance with applicable laws and regulations [2]